文献速递胸部肿瘤

转移性非小细胞肺癌试验中免疫检查点抑制剂、靶向治疗与传统治疗的里程碑分析:一项Meta分析

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
PubMed 文献 · JAMA Oncol · 2017-08-10

该Meta分析纳入2003年至2016年提交美国食品药品监督管理局的25项随机临床试验、20013例晚期肺癌患者,评估里程碑率作为中间终点的价值。12个月和9个月总生存里程碑率与总生存风险比呈中度相关,而9个月无进展生存和6个月客观缓解率里程碑率与总生存风险比无关联。

要点

  • 12个月总生存里程碑率与总生存风险比中度相关(R²=0.80)。
  • 9个月无进展生存和6个月客观缓解率里程碑率与总生存风险比无关联。
  • 免疫治疗试验较化疗总生存风险比0.69,靶向治疗试验较化疗无进展生存风险比0.48。

核心结论

  • 12个月或9个月总生存里程碑率与总生存风险比呈中度关联,而9个月无进展生存或6个月客观缓解率里程碑率与总生存风险比无关联。
  • 12个月总生存与总生存风险比关联最强,但可能不是未来试验的最佳时间点。
  • 里程碑率可作为补充工具总结或解读试验结果,或作为探索性研究的次要终点。

研究设计与样本

  • Meta分析,纳入2003年1月1日至2013年12月31日提交美国食品药品监督管理局的14项随机临床试验,以及2014年1月1日至2016年12月31日提交的11项随机临床试验。
  • 共25项随机临床试验、20013例晚期肺癌患者(65.4%男性,34.6%女性;平均年龄60岁,范围18-92岁)。

主要发现

  • 12个月总生存里程碑率与总生存风险比中度相关(R²=0.80;95%CI,0.63-0.91)。
  • 9个月总生存里程碑率与总生存风险比中度相关(R²=0.67;95%CI,0.49-0.82)。
  • 9个月无进展生存里程碑率与总生存风险比无关联(R²=0.19;95%CI,0.03-0.49)。
  • 6个月客观缓解率与总生存风险比无关联(R²=0.05;95%CI,0.0001-0.31)。
  • 免疫治疗试验较化疗总生存风险比0.69(95%CI,0.63-0.75),无进展生存风险比0.82(95%CI,0.76-0.89);靶向治疗试验较化疗总生存风险比0.98(95%CI,0.80-1.19),无进展生存风险比0.48(95%CI,0.42-0.56)。

关键数值与推荐

  • 12个月总生存里程碑率与总生存风险比的R²=0.80(95%CI,0.63-0.91)。
  • 9个月总生存里程碑率与总生存风险比的R²=0.67(95%CI,0.49-0.82)。
  • 9个月无进展生存里程碑率与总生存风险比的R²=0.19(95%CI,0.03-0.49)。
  • 6个月客观缓解率与总生存风险比的R²=0.05(95%CI,0.0001-0.31)。
  • 免疫治疗试验较化疗总生存风险比0.69(95%CI,0.63-0.75),无进展生存风险比0.82(95%CI,0.76-0.89);靶向治疗试验较化疗总生存风险比0.98(95%CI,0.80-1.19),无进展生存风险比0.48(95%CI,0.42-0.56)。

临床怎么用

  • 作者认为里程碑率可作为补充工具总结或解读试验结果,或作为探索性研究的次要终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC). OBJECTIVE: To explore milestone rate, a proposed intermediate end point for immunotherapy trials. DATA SOURCES: Trials submitted to the US Food and Drug Administration with more than 150 patients and in which the intention-to-treat population was assessed were identified. STUDY SELECTION: An initial meta-analysis identified 14 randomized clinical trials for treatment of mNSCLC with active controls submitted to the US Food and Drug Administration from January 1, 2003, through December 31, 2013. An additional 11 randomized clinical trials submitted from January 1, 2014, through December 31, 2016 were included. DATA EXTRACTION AND SYNTHESIS: Two investigators abstracted data and pooled data to compare trial-level milestone ratios with conventional end points. MAIN OUTCOMES AND MEASURES: Trial-level milestone ratios for milestone rates were calculated for overall response rate (ORR) within 6 months, 9-month progression-free survival (PFS), 9-month overall survival (OS), and 12-month OS. A weighted linear regression model evaluated associations between milestone ratios and hazard ratios (HRs). Experimental and control arms of trials testing immunotherapy, targeted therapy, and other trials were pooled to compare Kaplan-Meier survival estimates in the 3 therapeutic classes. RESULTS: A total of 20 013 unique patients (65.4% male and 34.6% female; mean age, 60 [range, 18-92] years) with advanced lung cancer were identified in 25 unique trials. A moderate association was observed between 12-month OS milestone ratio and OS HR (R2 = 0.80; 95% CI, 0.63-0.91) and 9-month OS milestone ratio and OS HR (R2 = 0.67; 95% CI, 0.49-0.82). No associations were observed between 9-month PFS milestone ratio and OS HR (R2 = 0.19; 95% CI, 0.03-0.49) or 6-month ORR and OS HR (R2 = 0.05; 95% CI, 0.0001-0.31). The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemotherapy revealed an OS HR of 0.69 (95% CI, 0.63-0.75) and PFS HR of 0.82 (95% CI, 0.76-0.89). Targeted therapy trials vs chemotherapy had an OS HR of 0.98 (95% CI, 0.80-1.19) and PFS HR of 0.48 (95% CI, 0.42-0.56). CONCLUSIONS AND RELEVANCE: This analysis of milestone rates suggests a moderate association between OS milestones at 12 or 9 months and OS HR but not 9-month PFS or 6-month ORR milestones and OS HR. Although OS at 12 months had the strongest association with OS HR, it may not be the optimal time for future trials, which will increasingly have immunotherapy as the control, deploy new biomarker-enrichment strategies, and likely enroll patients with longer survival. Milestone rates may be useful as a complementary tool to summarize or interpret trial results or as a secondary end point in exploratory studies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Blumenthal GM, Zhang L, Zhang H, et al. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA Oncol. 2017. PMID: 28617920. doi:10.1001/jamaoncol.2017.1029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。